comprehensive -WSS

comprehensive

author：focus 2025-09-30 17:03:42 - browse：63798

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Neuroscience renaissance leads to new crop of psychiatric drugs

hotspot

WSS

Children’s Hospital revives plan for pedestrian bridge

China dismisses criticism of top diplomat's comments appearing to push for race

Condition critical? Britain's beloved but battered National Health Service turns 75

Using force crossed my mind when examining a defiant young patient

Elisabeth Bik tackles the widespread issue of research misconduct

Search warrant issued in 1996 disappearance of Kristin Smart

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Sports medicine is finally prioritizing gender equality

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

Virginia high school admissions case could be legal follow

Adele warns fans about throwing things at performers onstage

United colonoscopy coverage change 'may cost lives,' doctors say

2 million sign

State Dept. review finds Biden bears some blame for Afghanistan failures

Ohio train derailment: Experts on toxic chemical risks

Drug repurposing or repositioning? The language matters

2 million sign

hotspot

Using force crossed my mind when examining a defiant young patient

Princess Kate attends Wimbledon with Roger Federer: See the photos

China dismisses criticism of top diplomat's comments appearing to push for race

Medicare Advantage isn’t working — for anyone

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

focus

Wikipedia

hotspot

leisure time